Evidence map›Paper›PMID 33159963›Full record

ArticleKidney international2021

Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism.

Pu Ni, Erica L Clinkenbeard, Megan L Noonan, Joseph M Richardville, Jeanette McClintick, Takashi Hato, Danielle Janosevic, Ying-Hua Cheng, Tarek M El-Achkar, Michael T Eadon and 2 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Pu NiDepartment of Medical and Molecular Genetics, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Erica L ClinkenbeardDepartment of Medical and Molecular Genetics, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Megan L NoonanDepartment of Medical and Molecular Genetics, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Joseph M RichardvilleDepartment of Medical and Molecular Genetics, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jeanette McClintickDepartment of Biochemistry and Molecular Biology, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Takashi HatoDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Danielle JanosevicDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ying-Hua ChengDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Tarek M El-AchkarDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Michael T EadonDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Pierre C DagherDepartment of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kenneth E WhiteDepartment of Medical and Molecular Genetics, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA; Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Electronic address: kenewhit@iu.edu.
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

PROBE DELIVERY COREP30DK079312 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MOLITORIS, BRUCE A · 2007 to 2021
$17.1M
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASEST32HL007910 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Roland W. Herzog, Reuben Kapur · 1999 to 2026
$7.6M
Changes in phosphate metabolism cause pathologic cardiac remodeling in chronic kidney disease (CKD)R01HL145528 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI FAUL, CHRISTIAN, WHITE, KENNETH E · 2019 to 2022
$2.4M
The role of antiviral programs in bacterial sepsisR01AI148282 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI HATO, TAKASHI · 2020 to 2024
$2.0M
Acute inhibition of renal gene expression to prevent nephrotoxicity.K08DK107864 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EADON, MICHAEL THOMAS · 2016 to 2020
$772k
Modulating purine metabolism to treat kidney injury in sepsis.K08DK113223 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI HATO, TAKASHI · 2017 to 2021
$757k
Novel Control of FGF23 in Metabolic Bone DiseaseR01DK112958 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2018 to 2020
$698k
FGF23 induction in phosphate-responsive single cellsR21AR075275 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2020 to 2021
$377k
Conditional Isolation of Fgf23 ActivityR21AR059278 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI WHITE, KENNETH E · 2010 to 2011
$373k
Therapeutic potential of HIF-PHDi in the control of bioactive FGF23 in CKD.F31DK122679 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NOONAN, MEGAN · 2019 to 2021
$90k
Protective pathways in sepsis-induced renal injuryI01BX002901 · VA · RLR VA MEDICAL CENTER · PI Takashi Hato · 2016 to 2026
–
BLRD VA I01 BX002901NHLBI NIH HHS R01 HL145528NHLBI NIH HHS T32 HL007910NIAID NIH HHS R01 AI148282NIAMS NIH HHS R21 AR059278NIAMS NIH HHS R21 AR075275NIDDK NIH HHS F31 DK122679NIDDK NIH HHS K08 DK107864NIDDK NIH HHS K08 DK113223NIDDK NIH HHS P30 DK079312NIDDK NIH HHS R01 DK112958
6 · The paper itself

Abstract

Fibroblast Growth Factor 23 (FGF23) is a bone-derived hormone that reduces kidney phosphate reabsorption and 1,25(OH)2 vitamin D synthesis via its required co-receptor alpha-Klotho. To identify novel genes that could serve as targets to control FGF23-mediated mineral metabolism, gene array and single-cell RNA sequencing were performed in wild type mouse kidneys. Gene array demonstrated that heparin-binding EGF-like growth factor (HBEGF) was significantly up-regulated following one-hour FGF23 treatment of wild type mice. Mice injected with HBEGF had phenotypes consistent with partial FGF23-mimetic activity including robust induction of Egr1, and increased Cyp24a1 mRNAs. Single cell RNA sequencing showed overlapping HBEGF and EGF-receptor expression mostly in the proximal tubule, and alpha-Klotho expression in proximal and distal tubule segments. In alpha-Klotho-null mice devoid of canonical FGF23 signaling, HBEGF injections significantly increased Egr1 and Cyp24a1 with correction of basally elevated Cyp27b1. Additionally, mice placed on a phosphate deficient diet to suppress FGF23 had endogenously increased Cyp27b1 mRNA, which was rescued in mice receiving HBEGF. In HEK293 cells with stable alpha-Klotho expression, FGF23 and HBEGF increased CYP24A1 mRNA expression. HBEGF, but not FGF23 bioactivity was blocked with EGF-receptor inhibition. Thus, our findings support that the paracrine/autocrine factor HBEGF could play novel roles in controlling genes downstream of FGF23 via targeting common signaling pathways.

Indexed as

Fibroblast Growth FactorsVitamin DAnimalsFibroblast Growth Factor-23GlucuronidaseHEK293 CellsHumansKidneyMiceMineralsPhosphatesFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseMineralsPhosphatesVitamin Dalpha-KlothoFGF23HBEGFkidneymineral metabolism

Identifiers

PMID33159963
PMCPMC7914218
OpenAlexW3097807426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.